CN Patent

CN114853784B — 一种十字孢碱类化合物及其制备方法与应用

Assigned to Key Laboratory of Natural Product Chemistry of Guizhou Academy of Sciences · Expires 2023-09-05 · 3y expired

What this patent protects

本发明公开了一种十字孢碱类化合物及其制备方法与应用；该化合物是以十字孢碱通过酰化反应和卤代反应制得；所公开的化合物对Flt3‑ITD突变的急性骨髓性细胞株MV4‑11均具有很强的抑制活性，对人外周血单核细胞PBMC抑制作用较弱，可应用于高效低毒预防和治疗白血病药物的开发。

USPTO Abstract

本发明公开了一种十字孢碱类化合物及其制备方法与应用；该化合物是以十字孢碱通过酰化反应和卤代反应制得；所公开的化合物对Flt3‑ITD突变的急性骨髓性细胞株MV4‑11均具有很强的抑制活性，对人外周血单核细胞PBMC抑制作用较弱，可应用于高效低毒预防和治疗白血病药物的开发。

Drugs covered by this patent

Patent Metadata

Patent number
CN114853784B
Jurisdiction
CN
Classification
—
Expires
2023-09-05
Drug substance claim
No
Drug product claim
No
Assignee
Key Laboratory of Natural Product Chemistry of Guizhou Academy of Sciences
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.